The ERBB4 and TP53 comutation was related to a higher PD-L1 score (proportion of PD-L1 positive cells) (ERBB4-WT VS MT group: p = 0.022, Fig. 2D) of advanced NSCLC patients. Here, ERBB4 is linked to non-small cell lung carcinoma.